Research
What happens when a company hands its duties to someone else
Drug sponsors are allowed to outsource almost anything, including their legal obligations. The rule that permits it also decides what happens to the parts nobody wrote down, and the default runs against the company doing the handing.
The sentence that outsourcing usually ends on
Ask who is answerable for something in a layered arrangement and the answer often arrives as a redirection. The pharmacy handles that. The lab handles that. Our partner handles that.
The investigational drug rules face the same problem, because running a trial is heavily outsourced work.
They solve it in about a hundred and fifty words, and the solution is worth borrowing as a way of thinking. Outsourcing is allowed, it has to be written down and itemized, and anything left off the page never moved.
What is being handed over
A sponsor's general responsibilities are stated in one sentence elsewhere in the same subpart. Selecting qualified investigators, and giving them what they need to conduct the investigation properly. Ensuring proper monitoring, and ensuring the work follows the plan and protocols. Maintaining an effective application. And ensuring the agency and all investigators are promptly informed of significant new adverse effects or risks.
Additional specific responsibilities are described throughout the rest of the part.
Those are the things a sponsor may transfer, and the rule does not limit which of them can go.
Who it can go to
The recipient has a defined name and a defined relationship.
A contract research organization means a person that assumes, as an independent contractor with the sponsor, one or more of the obligations of a sponsor.
The definition lists what that typically covers: design of a protocol, selection or monitoring of investigations, evaluation of reports, and preparation of materials to be submitted to the agency.
Independent contractor is doing real work in that sentence. The arrangement is between two separate parties, which is exactly why the rule then insists the terms be written down.
The writing requirement, and the itemization
A sponsor may transfer responsibility for any or all of the obligations in the part to a contract research organization. Any such transfer must be described in writing.
The rule then splits into two cases, and the difference between them is the whole point.
Where not all obligations are transferred, the writing must describe each of the obligations being assumed by the organization.
Where all obligations are transferred, a general statement that all obligations have been transferred is acceptable.
So a partial handover has to be enumerated, item by item. Only a total handover can be described in a sentence, and only because there is nothing left to be ambiguous about.
The default that decides the arguments
Then comes the sentence that makes the rest enforceable.
Any obligation not covered by the written description is deemed not to have been transferred.
Silence therefore has a fixed meaning, and it is not a shared or unsettled one. A duty nobody wrote down stayed exactly where it started.
That reverses the usual dynamic of a layered arrangement, where an unrecorded responsibility becomes whatever each party finds convenient afterward.
It also removes the incentive to be vague. A sponsor that wants to be relieved of a duty has to name it, and naming it is the act that moves it.
What the contractor picks up along with the work
Transferring a duty does not create a party who does the work without carrying the consequences.
A contract research organization that assumes any obligation of a sponsor must comply with the specific regulations applicable to that obligation.
And it is subject to the same regulatory action as a sponsor for failure to comply with any obligation it assumed.
The rule then generalizes that in a single line. All references to sponsor in the part apply to a contract research organization to the extent it has assumed one or more of the sponsor's obligations.
So the regulation follows the work rather than the name on the letterhead. Whoever holds the duty is read into every rule that mentions the role.
The transfer is declared on the front page
A written contract between two companies would be invisible to a regulator, so the arrangement has to be disclosed in the filing itself.
The cover sheet of the application carries it. Where a sponsor has transferred any obligations for the conduct of any clinical study, the sheet gives the name and address of the organization, identifies the study, and lists the obligations transferred.
The same shortcut applies as in the contract. If all obligations for the study have been transferred, a general statement of the transfer may be submitted in place of a listing.
The result is that the regulator can see the division of labor at the top of the file, before reading anything about the drug.
What the sponsor keeps in practice
Even where much of the work moves, the surrounding sections make certain duties hard to make disappear.
The sponsor selects only investigators qualified by training and experience as appropriate experts to investigate the drug, and selects a monitor qualified by training and experience to monitor the progress of the investigation.
The sponsor monitors the progress of all clinical investigations being conducted under its application.
And the rule prescribes what happens on discovering a problem. A sponsor may find that an investigator is not complying with the signed agreement, the general investigational plan, or the requirements. It must then promptly either secure compliance, or discontinue shipments to that investigator and end their participation.
Where participation ends, the sponsor must require the investigator to dispose of or return the drug, and must notify the agency.
Those duties can be transferred in writing like any other. What cannot happen is for them to become nobody's, because the default sends anything unwritten back to the sponsor.
The questions this makes askable
Nothing in this section reaches a consumer transaction. Its value is as a template for what a serious division of responsibility looks like when it is written properly.
It has four features. The arrangement is in writing. A partial handover is itemized rather than summarized. Anything unlisted stays with the original party. And the party doing the work is answerable for it under the same rules.
A reader looking at any layered arrangement can ask for those four in turn. Which entity holds this duty, is that recorded anywhere, is the list specific or general, and who answers if it is not done.
The strength of the regulatory version is that the last question has an answer even when nobody planned one. That is the part most commercial arrangements leave open.
Key takeaways
- A sponsor may transfer any or all of its regulatory obligations to a contract research organization, which takes them on as an independent contractor.
- Every transfer must be described in writing, and a partial transfer must describe each obligation being assumed.
- Any obligation not covered by the written description is deemed not to have been transferred, so silence returns the duty to the sponsor.
- A contract research organization that assumes an obligation is subject to the same regulatory action as a sponsor for failing to meet it.
- References to sponsor throughout the part apply to that organization to the extent it has assumed obligations.
- The transfer is disclosed on the application's cover sheet, naming the organization, the study and the obligations moved.
- A sponsor discovering investigator noncompliance must either secure compliance or stop shipments, end that participation, recover the drug and notify the agency.
Frequently asked questions
Can a drug sponsor outsource its legal obligations?
Yes. The rule allows a sponsor to transfer responsibility for any or all of its obligations under the part to a contract research organization. That means a person that assumes one or more of those obligations as an independent contractor. It does not limit which obligations may be transferred.
Does the transfer have to be in writing?
Yes, and the level of detail depends on how much is being transferred. Where not all obligations are transferred, the writing must describe each obligation being assumed. Where all obligations are transferred, a general statement to that effect is acceptable, because there is nothing left to leave ambiguous.
What happens to a duty nobody wrote down?
It stays where it started. The rule states that any obligation not covered by the written description is deemed not to have been transferred. Silence has a fixed meaning rather than an arguable one, and the default runs against the party seeking to be relieved of the duty.
Is the contractor answerable, or only the sponsor?
Both, for their own parts. An organization that assumes an obligation must comply with the specific regulations applicable to it, and is subject to the same regulatory action as a sponsor for failing to. All references to sponsor in the part apply to that organization to the extent it has assumed obligations.
Does the regulator get to see the arrangement?
Yes, on the cover sheet of the application. Where obligations for a study have been transferred, the filing gives the organization's name and address, identifies the study, and lists the obligations transferred. A general statement is allowed only where all obligations for that study went across.
What must a sponsor do if an investigator is not complying?
Act promptly, one of two ways. Either secure compliance, or discontinue shipments of the drug to that investigator and end their participation in the investigation. If participation ends, the sponsor must require the investigator to dispose of or return the drug and must notify the agency.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- 21 CFR 312.52 — Transfer of obligations to a contract research organization — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 21 CFR 312.50 — General responsibilities of sponsors — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 21 CFR 312.56 — Review of ongoing investigations — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 21 CFR 312.23 — IND content and format, whose cover sheet discloses any transfer of obligations — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026